Your session is about to expire
← Back to Search
Other
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg for Obesity
Phase 2
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
BMI 30.0 - 45.0 kg/m^2 (both inclusive) at the screening visit.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomisation (week 24) to end of treatment (week 40)
Awards & highlights
Study Summary
This trial is testing a new weight-loss drug against a placebo. Participants will receive 2 injections per week for 26 weeks and have 17 clinic visits. There are restrictions for women who are pregnant or may become pregnant during the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
BMI 30.0 or greater kg/m^2 at the screening visit.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from randomisation (week 24) to end of treatment (week 40)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomisation (week 24) to end of treatment (week 40)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Part 1: Number of treatment-emergent adverse events (TEAEs)
Secondary outcome measures
Part 2: Change in HbA1c
Part 2: Change in body weight
Part 2: Change in fasting insulin
+10 moreTrial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: Semaglutide 2.4 mg and NNC0165-1875 2.0 mgExperimental Treatment1 Intervention
Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
Group II: Semaglutide 2.4 mg and NNC0165-1875 1.0 mgExperimental Treatment1 Intervention
Participants will receive two doses of NNC0165-1875 as an add on to semaglutide s.c. 2.4 mg
Group III: Semaglutide 2.4 mg and placebo 1.0 mg(NNC0165-1875 1.0 mg)Placebo Group1 Intervention
Participants will receive placebo as an add on to semaglutide 2.4 mg.
Group IV: Semaglutide 2.4 mg and placebo 2.0 mg(NNC0165-1875 2.0 mg)Placebo Group1 Intervention
Participants will receive placebo as an add on to semaglutide 2.4 mg.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
2021
Completed Phase 2
~120
Semaglutide 2.4 mg and NNC0165-1875 2.0 mg
2021
Completed Phase 2
~120
Find a Location
Who is running the clinical trial?
Novo Nordisk A/SLead Sponsor
1,503 Previous Clinical Trials
2,385,694 Total Patients Enrolled
140 Trials studying Obesity
131,575 Patients Enrolled for Obesity
Clinical Transparency (dept. 1452)Study DirectorNovo Nordisk A/S
56 Previous Clinical Trials
45,000 Total Patients Enrolled
10 Trials studying Obesity
18,258 Patients Enrolled for Obesity
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
Utah
North Carolina
Illinois
Other
How old are they?
65+
18 - 65
What site did they apply to?
Novo Nordisk Investigational Site
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Why did patients apply to this trial?
Tried and failed to lose weight and have heard good things about these types of drugs.
PatientReceived no prior treatments
How responsive is this trial?
Typically responds via
Email
Most responsive sites:
- Novo Nordisk Investigational Site: < 48 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger